Presentation is loading. Please wait.

Presentation is loading. Please wait.

CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer  Shannon Otsuka, MSc, Alexander C.

Published byMay Cooper Modified over 5 years ago

Similar presentations

Presentation on theme: "CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer  Shannon Otsuka, MSc, Alexander C."— Presentation transcript:

1 CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer  Shannon Otsuka, MSc, Alexander C. Klimowicz, PhD, Karen Kopciuk, PhD, Stephanie K. Petrillo, MSc, Mie Konno, BSc, Desiree Hao, MD, FRCPC, Huong Muzik, BSc, Erin Stolte, BSc, William Boland, BSc, Don Morris, PhD, MD, FRCPC, Anthony M. Magliocco, MD, FRCPC, D. Gwyn Bebb, MA, BMBCh, PhD, FRCPC  Journal of Thoracic Oncology  Volume 6, Issue 7, Pages (July 2011) DOI: /JTO.0b013e a99 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier survival curve comparing the overall survival of the tissue array (TA) and non-TA cohorts. The curves never deviate more than 10% over the study duration. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e a99) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 CXCR4 immunohistochemistry (IHC) staining. A, CXCR4 staining in positive control Hela cells and tonsil tissue with and without the primary antibody. B, Interrogation of non-small cell lung cancer (NSCLC) samples on tissue microarray (TMA) for CXCR4 expression by IHC using the HistoRx/AQUA platform. CXCR4 is expressed in normal lung tissue only in the endothelial cells and is frequently expressed in NSCLC with a cytomembranous distribution. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e a99) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier survival curves comparing the overall survival between the high and low CXCR4 expression groups: (A) whole tissue microarray (TMA) cohort, (B) females, (C) males. (D) Summary table of the median overall survival and HRs for high and low expressing groups stratified on gender. High expressing females have a 5.4 times increased risk of death compared with the low expressors and a median overall survival (MOS) of only 1.6 months. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e a99) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer  Shannon Otsuka, MSc, Alexander C."

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma  Daniel L. Albertus, BS, Christopher.

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma  Daniel L. Albertus, BS, Christopher.
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy  Jun.

Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy  Jun.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Similar presentations

Ads by Google